Pharmaceutical Expenditure on Drugs for Rare Diseases in Canada: A Historical (2007–13) and Prospective (2014–18) MIDAS Sales Data Analysis

Orphanet Journal of Rare Diseases - United Kingdom
doi 10.1186/s13023-016-0450-y
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Factors Associated With Positive and Negative Recommendations for Cancer and Non-Cancer Drugs for Rare Diseases in Canada

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2019English

Pharmaceutical Expenditure

Health at a Glance: Asia/Pacific
2012English

Rising Expenditure on Drugs

BMJ
1965English

Pharmaceutical Expenditure and Policies

OECD Health Working Papers
2016English

The Second French Plan for Rare Diseases 2011-2014

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2012English

First International South Caucasian Conference on Rare Diseases and Orphan Drugs

European Journal of Pediatrics
Child HealthPediatricsPerinatology
2010English

Payer Management and Pricing Dynamics for Non-Oncology Pharmacy Benefit Orphan Drugs for Rare Diseases in the United States Launched 2004-2014

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Expenditure on Pharmaceuticals Per Capita, 2007

Health at a Glance 2009
2009English

Inpatient Perception on Hospitalization Experience Across US 50 States: Analysis of the Historical Series From 2007 to 2014

South Asian Research Journal of Applied Medical Sciences
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy